EPISODE · Jun 19, 2024 · 10 MIN
Highlights from ASCO Annual Meeting 2024, Leukemia Edition
from Meeting Mic · host Healio
In this episode of Meeting Mic, we bring you pearls and perspectives from the 2024 ASCO Annual Meeting with a focus on leukemia, as well as Healio's top headlines from the meeting. Jorge E. Cortes, MD, discusses how asciminib demonstrated superior efficacy to standard first-line therapies for certain patients with newly diagnosed chronic myeloid leukemia. :27 Oreofe O. Odejide, MD, MPH, highlights the importance of this study. 3:30 Read the full coverage here: https://www.healio.com/news/hematology-oncology/20240531/asciminib-may-transform-treatment-paradigm-for-chronic-myeloid-leukemia New approach 'redefining what is a suitable donor' for stem cell transplant Source: Al Malki MM, et al. Abstract 6503. Presented at: ASCO Annual Meeting; May 30 – June 4, 2024; Chicago. Disclosures: Cortes reports research funding to his institution from or consultant/advisory roles with Gilead Sciences, Jazz Pharmaceuticals, Novartis, Pfizer, Takeda and other companies.
NOW PLAYING
Highlights from ASCO Annual Meeting 2024, Leukemia Edition
No transcript for this episode yet
Similar Episodes
Feb 26, 2026 ·51m
Feb 25, 2026 ·3m
Feb 25, 2026 ·5m
Feb 25, 2026 ·27m
Feb 25, 2026 ·37m
Feb 25, 2026 ·109m